Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Notoginsenoside Fe is a minor dammarane-type triterpenoid saponin primarily isolated from the roots, leaves, and flowers of *Panax notoginseng* and *Panax japonicus*. It is frequently identified as a bioactive metabolite generated through the biotransformation of major ginsenosides, such as ginsenoside Rc, by gut microbiota or specific enzymatic processes. Research has highlighted its potential therapeutic utility in metabolic disorders, particularly obesity, where it has been shown to reduce food intake and body weight by activating energy-sensing neurons in the paraventricular nucleus (PVH) of the hypothalamus. Beyond its metabolic effects, notoginsenoside Fe exhibits anti-inflammatory, hemostatic, and anti-tumor activities. It has been studied for its ability to inhibit xanthine oxidase, making it a candidate for gout treatment, and for its inhibitory effects on lung adenocarcinoma cell proliferation. It is also a component of several traditional Chinese medicine (TCM) formulations investigated for acute lung injury and type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on notoginsenoside Fe.